LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Johns Hopkins Launches New COVID-19 Testing Insights Initiative

By LabMedica International staff writers
Posted on 09 May 2020
Image: Johns Hopkins Launches New COVID-19 Testing Insights Initiative (Photo courtesy of Johns Hopkins University)
Image: Johns Hopkins Launches New COVID-19 Testing Insights Initiative (Photo courtesy of Johns Hopkins University)
Johns Hopkins University (Baltimore, MD, USA) has launched the COVID-19 Testing Insights Initiative, a one-stop resource hub that fills the void of publicly-available information about COVID-19 testing data and offers critical insights, resources, and expert analysis about COVID-19 testing in the US.

In the coming weeks and months, viral tests for the presence of COVID-19 infection as well as serological tests for antibodies and possible immunity will be critical to measure the spread of the disease. Governments, businesses, and families will rely on data from these tests as well as answers to questions about testing capacity as they make decisions about the path forward. However, local testing data are not currently publicly available, and a comprehensive set of these data—paired with expert analysis and guidance—does not exist in one place. The Testing Insights Initiative aims to fill this void.

Through dynamic, continuously updated data visualizations, the Testing Insights Initiative offers a new, intuitive way to view and understand key data and insights to inform public policies and responses to the pandemic. The new initiative will be housed on the existing Johns Hopkins Coronavirus Resource Center webpage, an established resource for the public, policymakers, and the media about COVID-19 that has been viewed more than 400 million times in less than two months and linked to by more than 8,000 other websites.

Visualizations will chart trends in the data and measure testing capacity and results, as well as the efficacy of policy responses in real time. The new initiative will include COVID-19 testing trends for each US state, a tracker following the development and approval of serology tests, and frequently asked questions about COVID-19 testing. Following the initiative's launch, the site will quickly expand to include analyses of countries around the world. The site will be continuously updated as new data become available.

"Through the COVID-19 Testing Insights Initiative, Johns Hopkins will provide the comprehensive view of the testing landscape needed to guide effective policy decisions and shape our collective path to recovery," said Ron Daniels, president of Johns Hopkins University.

"The development and implementation of viral and serological tests are only half the battle," said Jennifer Nuzzo, senior scholar at the Johns Hopkins Center for Health Security and an associate professor at the Johns Hopkins Bloomberg School of Public Health. "The data from these tests must play a large role in decisions about our future, yet a complete set of these data are not currently publicly available. This initiative will fill that gap and provide essential insights to the public health community."

Related Links:
Johns Hopkins University

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Clinical Chemistry System
P780

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more